Briefly noted: A Meyer et al. Ann Intern Med. 2018. DOI: 10.7326/M18-1512
Abstract link: Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study
In this study with 5050 patients, based on review of an administration database, the authors found the following:
- In multivariable analysis of the primary outcome, CT-P13 (biosimilar) was equivalent to infliximab reference product (RP) (HR, 0.92 [95% CI, 0.85 to 0.99]). 1147 patients in the RP group and 952 patients in the CT-P13 group met the composite end point (including 838 and 719 hospitalizations, respectively).
- No differences in safety outcomes were observed between the 2 groups: serious infections (HR, 0.82 [CI, 0.61 to 1.11]), tuberculosis (HR, 1.10 [CI, 0.36 to 3.34]), and solid or hematologic cancer (HR, 0.66 [CI, 0.33 to 1.32]).
The authors conclude that “real-world data indicates that the effectiveness of CT-P13 is equivalent to that of RP for infliximab-naive patients with CD.”
Related blog posts:
- Interchangeability, Immunogenecity and Infliximab Biosimilars
- Biosimilars: “The Horse is out of the barn”
- Pediatric Views on Biosimilars and Interchangeability
- Role of Biosimilars in Inflammatory Bowel Disease | gutsandgrowthEuropean Experience with Biosimilars
- Biosimilars -Position Statement
- FDA approves Amjevita (Humira biosimilar)
- Bioequivalence of Biosimilars
Pingback: ESPGHAN Position Paper: Biosimilars in Pediatric Inflammatory Bowel Disease | gutsandgrowth
Pingback: IBD Update March 2019 | gutsandgrowth
Pingback: IBD Pediatric Costs & Cannabis Still No Data for IBD | gutsandgrowth